Yesterday it was reported that the EVP, CFO and Sec. of ChemoCentryx (CCXI), Susan Kanaya, exercised options to buy 3,037 CCXI shares at $3.57 a share, for a total transaction value of $10.84K.
This recent transaction increases Susan Kanaya’s holding in the company by 4.17% to a total of $822.6K.
See today’s analyst top recommended stocks >>
CCXI’s market cap is $538.1M and the company has a P/E ratio of 42.98. The Company has a Price to Book ratio of 25.4394. Currently, ChemoCentryx has an average volume of 104.2K.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $18.13, reflecting a 67.3% upside. Three different firms, including Piper Jaffray and Leerink Partners, currently also have a Buy rating on the stock.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact.
